{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:10:11Z","timestamp":1781896211948,"version":"3.54.5"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1097\/ftd.0000000000000024","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T10:02:24Z","timestamp":1387188144000},"page":"3-9","source":"Crossref","is-referenced-by-count":5,"title":["Slow Carbamazepine Clearance in a Nonadherent Malay Woman With Epilepsy and Thyrotoxicosis"],"prefix":"10.1097","volume":"36","author":[{"given":"Li-Ling","family":"Yeap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kheng-Seang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ching","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hui-Ping Khor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoke-Lin","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":". The importance of drug interactions in epilepsy therapy.","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"R2-2-20210129","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":". Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R3-2-20210129","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.yebeh.2012.08.027","article-title":"Adherence to antiepilepsy drug therapy.","volume":"25","author":"Faught","year":"2012","journal-title":"Epilepsy Behav"},{"key":"R4-2-20210129","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.yebeh.2008.03.009","article-title":". Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians.","volume":"13","author":"Hovinga","year":"2008","journal-title":"Epilepsy Behav"},{"key":"R5-2-20210129","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/nedt.2007.3.1.117","article-title":"Managing patient adherence and quality of life in epilepsy.","volume":"3","author":"Eatock","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"D237","DOI":"10.1093\/nar\/gkp970","article-title":". SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions.","volume":"38","author":"Preissner","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.clpt.2006.08.013","article-title":". Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine.","volume":"80","author":"Oscarson","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R9-2-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/08998280.2000.11927719","article-title":"Drug interactions due to cytochrome P450.","volume":"13","author":"Ogu","year":"2000","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"R10-2-20210129","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"key":"R13-2-20210129","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/mend-4-3-447","article-title":". Pituitary regulation of the male-specific steroid 6 beta-hydroxylase P-450 2a (gene product IIIA2) in adult rat liver. Suppressive influence of growth hormone and thyroxine acting at a pretranslational leve.","volume":"4","author":"Waxman","year":"1990","journal-title":"Mol Endocrinol"},{"key":"R14-2-20210129","first-page":"2411","article-title":". Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes.","volume":"83","author":"Liddle","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-2-20210129","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270009344336","article-title":". Effect of thyroid hormone on the activity of CYP3A enzyme in humans.","volume":"50","author":"Takahashi","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R16-2-20210129","first-page":"337","article-title":"Hepatic dysfunction in hyperthyroidism.","volume":"7","author":"Khemichian","year":"2011","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"suppl 1","key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1111\/j.1365-2125.2001.00394.x","article-title":"Therapeutic drug monitoringantiepileptic drugs.","volume":"52","author":"Eadie","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical pharmacokinetics of carbamazepine.","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","article-title":"Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.","volume":"11","author":"Bertilsson","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"R23-2-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0924-977X(97)00406-9","article-title":". Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans.","volume":"7","author":"Delcker","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"R24-2-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2710.2004.00557.x","article-title":". Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.","volume":"29","author":"Jiao","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00007691-200306000-00005","article-title":". Population pharmacokinetics of carbamazepine in Chinese epilepsy patients.","volume":"25","author":"Jiao","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R26-2-20210129","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.0306-5251.2001.01396.x","article-title":"Population pharmacokinetics of carbamazepine in Singapore epileptic patients.","volume":"51","author":"Chan","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R27-2-20210129","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011569703060","article-title":". Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults.","volume":"28","author":"Reith","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2125.1992.tb04089.x","article-title":". Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.","volume":"33","author":"Kudriakova","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"R29-2-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0920-1211(96)00011-3","article-title":". Dose-dependent metabolism of carbamazepine in humans.","volume":"24","author":"Bernus","year":"1996","journal-title":"Epilepsy Res"},{"key":"R33-2-20210129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/FTD.0b013e31815c15f3","article-title":". Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data.","volume":"29","author":"Vucicevic","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R34-2-20210129","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.arcmed.2003.09.016","article-title":". Pharmacokinetic study of carbamazepine and its carbamazepine 10,11-epoxide metabolite in a group of female epileptic patients under chronic treatment.","volume":"35","author":"Moreno","year":"2004","journal-title":"Arch Med Res"},{"key":"R35-2-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1528-1167.2008.01716.x","article-title":". The clinical impact of pharmacogenetics on the treatment of epilepsy.","volume":"50","author":"Loscher","year":"2009","journal-title":"Epilepsia"},{"key":"R36-2-20210129","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1600-0404.2006.00761.x","article-title":". Intestinal expression of cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition.","volume":"115","author":"Simon","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"R37-2-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/14622416.7.4.551","article-title":". ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.","volume":"7","author":"Seo","year":"2006","journal-title":"Pharmacogenomics"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/00498250802617746","article-title":". Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine.","volume":"39","author":"Maekawa","year":"2009","journal-title":"Xenobiotica"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1124\/dmd.110.034140","article-title":". CYP3A416 and CYP3A418 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.","volume":"38","author":"Maekawa","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1124\/dmd.107.016733","article-title":". The CYP3A418 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals.","volume":"35","author":"Lee","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R41-2-20210129","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.9210","article-title":". Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.","volume":"23","author":"Fukushima-Uesaka","year":"2004","journal-title":"Hum Mutat"},{"key":"R42-2-20210129","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":". Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R43-2-20210129","first-page":"39","article-title":". Association study of CYP3A5 genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients.","volume":"16","author":"Meng","year":"2011","journal-title":"Neurol Asia"},{"key":"R44-2-20210129","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2710.2009.01057.x","article-title":". Effect of CYP3A53 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients.","volume":"34","author":"Park","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"R45-2-20210129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clpt.2006.02.009","article-title":". Effect of CYP3A53 on carbamazepine pharmacokinetics in Japanese patients with epilepsy.","volume":"79","author":"Seo","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R46-2-20210129","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00228-004-0878-1","article-title":". Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients.","volume":"61","author":"Nakajima","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"R47-2-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/hmg\/3.3.421","article-title":". Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants.","volume":"3","author":"Hassett","year":"1994","journal-title":"Hum Mol Genet"},{"key":"R48-2-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs.12.180","article-title":". Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.","volume":"14","author":"Puranik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"R49-2-20210129","first-page":"191","article-title":". The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy.","volume":"8","author":"Sterjev","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R50-2-20210129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":". A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia.","volume":"12","author":"DiBonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"key":"R51-2-20210129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0920-1211(90)90088-D","article-title":". Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine.","volume":"6","author":"Persson","year":"1990","journal-title":"Epilepsy Res"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T17:05:16Z","timestamp":1716311116000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201402000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000024","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}